Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care
- 9 January 2018
- journal article
- letter
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 47 (5) , 418-421
Abstract
As patents on originator biological disease-modifying anti-rheumatic drugs (bDMARDs) expire, biosimilar drugs are marketed. As a result of the complex manufacturing processes, a biosimilar is not c...Keywords
Funding Information
- AbbVie (Unrestricted grant)
This publication has 4 references indexed in Scilit:
- A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registryAnnals of the Rheumatic Diseases, 2017
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialThe Lancet, 2017
- The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIOClinical Epidemiology, 2016
- Biosimilars in immune‐mediated inflammatory diseases: initial lessons from the first approved biosimilar anti‐tumour necrosis factor monoclonal antibodyJournal of Internal Medicine, 2015